Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
, , , , -
A 56 percentage point difference is real and clinically meaningful at scale especially for patients with severe obesity who need maximum weight loss
(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
GLP-1 drugs like Ozempic and Wegovy have helped millions of Americans lose weight and take control of their healthbut what happens when you stop taking them
US$ 26.16
US$ 22.37
US$ 22.45
US$ 25.70
US$ 25.48
US$ 23.15
US$ 20.63
US$ 25.52
US$ 22.70
US$ 22.08
